Latest News
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook
12 May 2026 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced late Monday that the US Biomedical Advanced Research and Development Authority (BARDA) has exercised contract options worth USD97m for the production and supply of ...
Cellular Intelligence and Novo Nordisk enter agreement to advance clinical-stage Parkinson's cell therapy
12 May 2026 - AI-native TechBio company Cellular Intelligence announced on Monday that it has acquired global rights to a clinical-stage cell therapy programme for Parkinson's disease from Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO...
Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954
12 May 2026 - Ranok Therapeutics, a US-based clinical-stage biotechnology company developing innovative therapies, announced on Monday the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the peer-reviewed journal Ca...
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
12 May 2026 - Clinical-stage biopharmaceutical company Transpire Bio Inc announced on Monday that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of the high-stren...
Hengrui Pharma and Bristol Myers Squibb agree to jointly advance oncology, haematology and immunology medicines
12 May 2026 - Chinese pharmaceutical company Hengrui Pharma (SH:600276) (HK:01276) and US biopharmaceutical company Bristol Myers Squibb (BMS) (NYSE:BMY) announced on Tuesday that they have entered into global strategic collaboration and licence agre...